以奥沙利铂为基础的联合化疗方案治疗晚期胃癌的临床对照研究  

Clinical controlled study of oxaliplatin combined chemotherapy in treatment of advanced gastric cancer

作　　者：刘艳[1] 刘佳丽[1] 许崇安[1] 李琳[1] 冯丹[1] 邢丽丽[1] 

机构地区：[1]中国医科大学附属第四医院肿瘤内科,辽宁沈阳110032

出　　处：《现代肿瘤医学》2011年第8期1595-1598,共4页Journal of Modern Oncology

摘　　要：目的:探讨奥沙利铂联合替加氟和亚叶酸钙方案治疗晚期胃癌的临床疗效和不良反应。方法:对60例晚期胃癌患者采用奥沙利铂联合亚叶酸钙和替加氟方案治疗(观察组),同时随机抽取既往在我院住院并采用顺铂联合表阿霉素和氟尿嘧啶(即经典ECF方案)治疗的晚期胃癌患者60例作为对照组,评价两组临床疗效和不良反应发生率差异。结果:观察组和对照组患者的临床有效率分别为63.3%(38/60)和40.0%(24/60),两组间差异有统计学意义(χ2=6.541,P=0.017);观察组患者的中位无进展生存期和中位生存期分别为7.7个月和11.6个月,对照组患者的中位无进展生存期和中位生存期分别为6.1个月和9.1个月,二者中位无进展生存期和中位生存期差异均有统计学意义(均P<0.001);观察组患者Karnofsky评分改善率明显优于对照组,二者间有统计学差异(χ2=9.855,P=0.003);观察组骨髓抑制发生率低于对照组(χ2=6.009,P=0.023),两组间其他不良反应发生率未见明显差异。结论:奥沙利铂联合替加氟和亚叶酸钙方案治疗晚期胃癌的临床疗效及安全性优于ECF方案,值得临床推广应用。Objective：To investigate the efficacy and safety of oxaliplatin combined with tegafur and leucovorin in treatment of patients with advanced gastric cancer.Methods：Sixty patients with advanced gastric cancer were treated with oxaliplatin combined with tegafur and leucovorin（observation group）.Meanwhile,we also randomly selected 60 patients with gastric cancer in our hospital who have recieved cisplatin combined with epirubicin and fluorouracil chemotherapy（ECF standard chemotherapy regimen） as control group,to evaluate the clinical efficacy and safety differences between two groups.Results： The clinical efficacy rates of observation group and control group were 63.3%（38/60） and 40.0%（24/60）,there was a significant differences between the two groups（P=0.017）.The median progression-free survival and median survival of patients in observation group were 7.7 months and 11.6 months,and the median progression-free survival and median survival of patients in control group were 6.1 months and 10.1 months,both median progression-free survival and median survival were statistically significant different（all P0.005）.The increased ratio of Karnofsky score of patients in observation group was higher than control group（P=0.003）.The incidence of myelosuppression in observation group was lower than control group（P=0.023）.There was no significant difference between the two groups on other adverse reaction rates.Conclusion：The efficacy and safety of oxaliplatin plus tegafur and leucovorin in the treatment of advanced gastric cancer is superior to classic ECF regimen,and worthy of clinical application.

关 键 词：奥沙利铂 替加氟 亚叶酸钙 晚期胃癌 疗效 

分 类 号：R730.3[医药卫生—肿瘤]